Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

PharmacoEconomics

Volumn 31, Issue 5, 2013, Pages 361-367

  Husereau, Don ^a,b,c,m   Drummond, Michael ^o   Petrou, Stavros ^d   Carswell, Chris ^e   Moher, David ^f   Greenberg, Dan ^g,h   Augustovski, Federico ^i,j   Briggs, Andrew H ^k   Mauskopf, Josephine ^l   Loder, Elizabeth ^m,n  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e ADIS INTERNATIONAL LIMITED   (New Zealand)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^j UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

^l RTI HEALTH SOLUTIONS   (United States)

^m Faulkner Hospital ^*  (Canada)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o UNIVERSITY OF YORK   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RESOURCE ALLOCATION;

EID: 84877965075     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0032-y     Document Type: Article

References (24)

1. Drummond MF, Sculpher MJ, Torrance G, O'Brien J, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005.
2. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244-58.
3. Rennie D, Luft HS. Pharmacoeconomic analyses. JAMA. 2000;283:2158-60.
4. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000;132:964.
5. Rosen AB, Greenberg D, Stone PW, Olchanski NV, Neumann PJ. Quality of abstracts of papers reporting original cost-effectiveness analyses. Med Decis Mak. 2005;25:424-8.
6. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012;1:60.
7. Drummond MF. A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? Pharmacoeconomics. 1998;14:1-9.
8. McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. The ISPOR good practices for quality improvement of cost-effectiveness research task force report. Value Health. 2009;12:1086-99.
9. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology. A report on principles. Ann Intern Med. 1995;123:61-70.
10. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-83.
11. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
12. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41.
13. Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, et al. Reporting format for economic evaluation: Part II: focus on modelling studies. Pharmacoeconomics. 1998;14:259-68.
14. Vintzileos AM, Beazoglou T. Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. Am J Obstet Gynecol. 2004;191:1070-6.
15. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21:165-71.
16. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8:521-33.
17. Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Evidence and value: impact on decisionmaking - the EVIDEM framework and potential applications. BMC Health Serv Rev. 2008;8:270.
18. Davis JC, Robertson MC, Comans T, Scuffham PA. Guidelines for conducting and reporting economic evaluation of fall prevention strategies. Osteoporos Int. 2010;22:2449-59.
19. Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.
20. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ. 2011;342:d1548.
21. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) - explanation and elaboration: a report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. Value in Health (forthcoming).
22. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7:e1000217.
23. Moher D, Weeks L, Ocampo M, et al. Describing reporting guidelines for health research: a systematic review. J Clin Epi 2011;64:718-42.
24. Campbell SM, Hann M, Roland MO, Quayle JA, Shekelle PG. The effect of panel membership and feedback on ratings in a two-round Delphi survey: results of a randomized controlled trial. Med Care. 1999;37:964-8.